Literature DB >> 25104859

Live and let die at TEMRA.

Frédéric Rieux-Laucat1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25104859      PMCID： PMC4126318          DOI： 10.1182/blood-2014-06-581637

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.

Authors:  Aude Magerus-Chatinet; Bénédicte Neven; Marie-Claude Stolzenberg; Cécile Daussy; Peter D Arkwright; Nina Lanzarotti; Catherine Schaffner; Sophie Cluet-Dennetiere; Filomeen Haerynck; Gérard Michel; Christine Bole-Feysot; Mohammed Zarhrate; Isabelle Radford-Weiss; Serge P Romana; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression.

Authors:  U Lopatin; X Yao; R K Williams; J J Bleesing; J K Dale; D Wong; J Teruya-Feldstein; S Fritz; M R Morrow; I Fuss; M C Sneller; M Raffeld; T A Fleisher; J M Puck; W Strober; E S Jaffe; S E Straus
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

3.  FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function.

Authors:  Aude Magerus-Chatinet; Marie-Claude Stolzenberg; Maria S Loffredo; Bénédicte Neven; Catherine Schaffner; Nicolas Ducrot; Peter D Arkwright; Brigitte Bader-Meunier; José Barbot; Stéphane Blanche; Jean-Laurent Casanova; Marianne Debré; Alina Ferster; Claire Fieschi; Benoit Florkin; Claire Galambrun; Olivier Hermine; Olivier Lambotte; Eric Solary; Caroline Thomas; Francoise Le Deist; Capucine Picard; Alain Fischer; Frédéric Rieux-Laucat
Journal:  Blood       Date:  2009-01-27       Impact factor: 22.113

4.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

5.  Human TCR alpha/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells.

Authors:  Anne Bristeau-Leprince; Véronique Mateo; Annick Lim; Aude Magerus-Chatinet; Eric Solary; Alain Fischer; Frédéric Rieux-Laucat; Marie-Lise Gougeon
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Autoimmune lymphoproliferative syndrome with somatic Fas mutations.

Authors:  Eliska Holzelova; Cédric Vonarbourg; Marie-Claude Stolzenberg; Peter D Arkwright; Françoise Selz; Anne-Marie Prieur; Stéphane Blanche; Jirina Bartunkova; Etienne Vilmer; Alain Fischer; Françoise Le Deist; Frédéric Rieux-Laucat
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

7.  Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency.

Authors:  Anne Rensing-Ehl; Simon Völkl; Carsten Speckmann; Myriam Ricarda Lorenz; Julia Ritter; Ales Janda; Mario Abinun; Hanspeter Pircher; Bertram Bengsch; Robert Thimme; Ilka Fuchs; Sandra Ammann; Andrea Allgäuer; Karim Kentouche; Andrew Cant; Sophie Hambleton; Claudia Bettoni da Cunha; Sebastian Huetker; Ingrid Kühnle; Arnulf Pekrun; Markus G Seidel; Michael Hummel; Andreas Mackensen; Klaus Schwarz; Stephan Ehl
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

Review 8.  Fas and Fas ligand: lpr and gld mutations.

Authors:  S Nagata; T Suda
Journal:  Immunol Today       Date:  1995-01

9.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Authors:  F Rieux-Laucat; F Le Deist; C Hivroz; I A Roberts; K M Debatin; A Fischer; J P de Villartay
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.